Individual Patient Expanded Access IND of Autologous HB-adMSCs for the Treatment of Systemic Lupus Erythematosus (SLE)

NO_LONGER_AVAILABLE

Conditions studied: System; Lupus Erythematosus

In brief

This protocol is part of an FDA Individual Patient Expanded Access IND. This study is to be conducted according to US and International Standards of Good Clinical Practice (FDA Title 21 part 312 and International Conference on Harmonization guidelines), applicable government regulations and Hope Biosciences Stem Cell Research Foundation policies and procedures.

Key facts

Study ID

NCT04907175

Run by

Hope Biosciences Research Foundation

Last updated by the study team

2025-09-29

Who can join

Age: 18 and older, up to 75. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Adult individual 18 years of age or older.
• Cognitively intact and capable of giving informed consent.
• Clinical diagnosis of Systemic Lupus Erythematosus.
• Subject has mesenchymal stem cells banked at Hope Biosciences.
• The patient accepts to receive treatment and to comply with follow-up visits.

You may not qualify if…

• Clinically significant, uncontrolled cardiovascular, lung, renal, hepatic, or endocrine diseases that in the opinion of the investigator may increase the risks associated with study participation.
• Active Alcohol or Drug addiction.
• Participation in concurrent interventional research studies during this study.
• Severe organ failure (heart, kidney or liver) confirmed by additional tests or medical history.
• Unwillingness to return for follow-up visits.

Where it is running

• Hope Biosciences Stem Cell Research Foundation — Sugar Land, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.